Entries |
Document | Title | Date |
20100240578 | ANTI-H5N1 INFLUENZA ACTIVITY OF THE ANTIVIRAL PROTEIN CYANOVIRIN - The invention is directed to a method of inhibiting prophylactically or therapeutically an H5N1 viral infection in a host, which method comprises administering to the host an anti-viral effective amount of an antiviral protein comprising the amino acid sequence of SEQ ID NO: 1 or a nucleic acid encoding the antiviral protein, as well as antiviral portions, variants, and conjugates thereof. | 09-23-2010 |
20100240579 | DETECTION OF CELL SURFACE BINDING MOLECULES USING A PHAGE DISPLAY BLOCKING ASSAY - The present invention relates to the use of a phage blocking assay to determine unknown binding molecule present on or in the surface of a cell, a non-infectious moiety, a bacteria, a virus, or another pathogen. In particular embodiments, the invention relates to the identification of unknown receptors on a cell or virus involved in infection. Further, it relates to the use of said binding molecules, for example virus binding molecules or cellular receptors and binding members with binding specificity to said binding molecules, for example antibodies, in methods of therapy. | 09-23-2010 |
20100249021 | METHOD AND MEDICAMENT FOR INHIBITING THE INFECTION OF INFLUENZA VIRUS - The invention relates to a process for inhibiting the infection of influenza viruses and a polypeptide or protein medicine used therein. More particularly, the invention involves a process for inhibiting the highly pathogenic avian influenza virus (such as H5N1 subtype) infection and human influenza virus (such as H1N1 subtype and H3N2 subtype) infection, as well as the polypeptide or protein involved therein, and a polynucleotide encoding the polypeptide or protein and a vector or host cell expressing said polypeptide or protein. | 09-30-2010 |
20100261640 | SOLUBLE AND MEMBRANE ANCHORED FORMS OF LASSA VIRUS SUBUNIT PROTEINS - The invention discloses compositions comprising soluble and membrane-anchored forms of Lassa virus (LASV) glycoprotein 1 (GP1), glycoprotein 2 (GP2), the glycoprotein precursor (GPC), the nucleocapsid protein (NP), and the nucleic acids encoding these proteins. This invention further relates to diagnostic and preventative methods using these compositions. Preventative methods include preparation of vaccines, as well as factors (e.g. small molecules) that inhibit LASV infectivity. Further, the invention relates to diagnostic and therapeutic antibodies including neutralizing antibodies for the prevention and treatment of infection by LASV and other arenaviruses. | 10-14-2010 |
20100317566 | COMPOSITIONS AND METHODS FOR TREATING AIDS OR CANCER BY INHIBITING THE SECRETION OF MICROPARTICLES - Novel peptides that inhibit the release of microparticles from cells are disclosed. The peptide contains at least one VGFPV motif at the N-terminal and has a length of 10-100 amino acids. Also disclosed is polynucleotide encoding the peptide, expression vectors carrying the polynucleotide, and methods for treating AIDS and tumors using the novel peptides. | 12-16-2010 |
20100317567 | DIAGNOSING AND PROTECTING HORSES AGAINST PAPILLOMAVIRUS - Compositions for conferring protection against Equus caballus papillomavirus (EcPV) and Bovine papillomavirus (BPV) infection in a subject are provided and include a virus-like particle assembled from an EcPV L1 protein and virus like particle assembled from a BPV L1 protein. Methods for protecting a subject against EcPV and BPV infection are further provided and include administering to the subject a composition comprised of a virus-like particle assembled from an EcPV L1 protein and virus like particle assembled from a BPV L1 protein. Methods of diagnosing EcPV and/or BPV infection in a subject are also provided and include providing a virus-like particle assembled from a papillomavirus L1 protein selected from an EcPV L1 protein and a BPV L1 protein; contacting the virus-like particle with serum from the subject; and identifying the subject as having an infection if an antibody capable of binding the virus-like particle is detected in the serum. | 12-16-2010 |
20110046042 | Long Interspersed Nuclear Element Polypeptide Compositions and Methods of Use Thereof - The present invention provides LINE polypeptides; and compositions, including immunogenic compositions, comprising a subject LINE polypeptide. The present invention provides a recombinant nucleic acid comprising a nucleotide sequence encoding a subject LINE polypeptide. A subject composition is useful for stimulating a T-cell immune response to a LINE peptide. The present invention further provides methods of stimulating an immune response in an individual to a retrovirus- or lentivirus-infected cell. The present invention further provides methods of treating cancers that are associated with tissues in which LINE polypeptides are aberrantly expressed. Also provided are methods of treating disorders, involving decreasing an immune response to a LINE polypeptide. | 02-24-2011 |
20110071073 | Detection of mutations in a gene associated with resistance to viral infection, OAS1 - A method for detecting a mutation related to the gene encoding OAS1. This and other disclosed mutations correlate with resistance of humans to viral infection including hepatitis C. Also provided is a therapeutic agent consisting of a protein or polypeptide encoded by the mutated gene, or a polynucleotide encoding the protein or polypeptide. Inhibitors of human OAS1, including antisense oligonucleotides, methods, and compositions specific for human OAS1, are also provided. | 03-24-2011 |
20110092414 | COMPOSITION FOR TREATING VIRUS INFECTION DISEASE COMPRISING JAB1 - Disclosed is a composition for treating or preventing a viral infection or associated disease comprising a Jab1 protein, a nucleic acid having a nucleotide sequence coding for a Jab1 protein or a recombinant virus expressing a Jab1 protein. | 04-21-2011 |
20110118175 | COMPETITIVE INHIBITORS OF INVARIANT CHAIN EXPRESSION AND/OR ECTOPIC CLIP BINDING - The invention relates to methods for modulating the immune function through targeting of CLIP molecules. The result is wide range of new therapeutic regimens for treating, inhibiting the development of, or otherwise dealing with, a multitude of illnesses and conditions, including autoimmune disease, cancer, Alzheimer's disease, allergic disease, transplant and cell graft rejection, HIV infection and other viral, bacterial, and parasitic infection, and AIDS. Methods are also provided for preparing a peptide having the property of being able to displace CLIP by feeding one or more peptide sequences into software that predicts MHC Class II binding regions in an antigen sequence and related products. | 05-19-2011 |
20110130327 | Multi-Arm Amines and Uses Thereof - Multi-arm amine compounds and compositions for enhancing intracellular, in vitro, and in vivo delivery of drug, active, and therapeutic substances including ribonucleic acids. This disclosure provides novel compounds and compositions for making and using delivery materials and carriers which increase the efficiency of delivery of biologically active and pharmacologically active molecules. Embodiments of this disclosure may further provide delivery of various therapeutic agents including nucleic acid therapeutics such as regulatory RNA, interfering RNA, and agents for RNAi, as well as other protein and peptide therapeutics. In some aspects, this disclosure provides multi-arm amine compounds and compositions which can enhance permeation of a drug substance. | 06-02-2011 |
20110130328 | FLAVIVIRUS FUSION INHIBITORS - The present invention provides an isolated peptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:36, as well as derivatives thereof comprising various N-terminal and C-terminal chemical moieties, substituted analogs thereof, and fragments thereof. The peptides of the invention are useful for treating and preventing a Flavivirus invention. Pharmaceutical compositions comprising the peptides, and methods of treating or preventing Flavivirus infections, are also provided. | 06-02-2011 |
20110136730 | "Method for screening compounds comprising the use of picornavirus protease 2A" - A method of screening compounds or molecules comprising the steps of: translating a sequence encoding the amino acid sequence comprising SEQ ID No. 29 in a translation system in the presence of a test compound or molecule; and analysing the translation product(s) for the presence of one or more of (a) a peptide comprising the amino acids Pro-Gly at the C terminus and a peptide comprising the amino acid Pro at the N terminus: or (b) a peptide comprising the amino acid sequence of SEQ ID No. 29. | 06-09-2011 |
20110144005 | NOVEL CYCLIC PEPTIDES - Compounds are disclosed of general formula (I): | 06-16-2011 |
20110152178 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR INFLUENZA VIRUS INFECTION - The present invention provides a self-assembly of a compound or of a pharmaceutically acceptable salt thereof, the compound being represented by formula (I) | 06-23-2011 |
20110160126 | Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders - Methods for treatment of diseases, including human immunideficiency virus infection, are provided. The disease are treated by administering conjugates containing as a ligand a chemokine receptor targeting agents, such as a chemokine, and a targeted agent, such as a toxin. | 06-30-2011 |
20110160127 | Prodrugs of Neuraminidase Inhibitors - A new class of neuramidase inhibitor prodrugs is provided characterized by a prodrug moiety of a carboxyl group modified to form a carbonyl ethoxy amino acid, a carbonyl ethoxy dipeptide or a carbonyl ethoxy tripeptide, a guanidine group modified to form a carbonyl ethoxy amino acid, a carbonyl ethoxy dipeptide, a carbonyl ethoxy tripeptide; a primary alcohol modified to form an esterified single amino acid, dipeptide or tripeptide of zanavimir of the unaltered therapeutic agent. Exemplary therapeutic agents so modified to form prodrugs include zanavimir, oseltamivir and peramivir. The prodrug has increased oral bioavailability relative to the unaltered neuraminidase inhibitor and is effective in the inhibition of viral infections involving neuraminidase in the viral reproductive cycle. | 06-30-2011 |
20110178003 | OPTIMIZED DENGUE VIRUS ENTRY INHIBITORY PEPTIDE (10AN) - The invention relates peptide entry inhibitors and methods of determining such inhibitors that are bindable to regions of viruses having class II E proteins, such as the dengue virus E protein, as candidates for in vivo anti-viral compounds. | 07-21-2011 |
20110183892 | METHODS FOR THE TREATMENT OF VIRAL CONDITIONS - The invention is directed to a method of stimulating PRF in a viral cell by administering an aminoglycoside antibiotic to said cell. In another embodiment, the invention is directed to a method of inhibiting viral replication by administering an aminoglycoside antibiotic to a viral cell. The invention is also directed to method of treating a viral infection in a patient suffering therefrom comprising administering to said patient an aminoglycoside antibiotic. | 07-28-2011 |
20110183893 | NON-NATURAL MIC PROTEINS - This invention describes soluble, monovalent, non-natural protein molecules that can activate NK cells and certain T-cells to attack specific cellular target cells by attaching the NKG2D-binding portions of monovalent MICA or MICB protein, i.e. their α1-α2 platform domain, to the intended target cell specifically. The α1-α2 domain is contiguous with a heterologous α3 domain that has been genetically modified to bind directly or indirectly to the extracellular aspect of the target cell, thereby serving as the targeting domain. The genetic modification to create a non-natural and non-terminal targeting motif within the α3 domain can include a portion of an antibody, another protein molecule or portion thereof, a peptide, or a non-natural, modified α3 domain of a MIC protein. | 07-28-2011 |
20110201547 | ENGINEERED POLYPEPTIDE AGENTS FOR TARGETED BROAD SPECTRUM INFLUENZA NEUTRALIZATION - The present invention provides novel agents for broad spectrum influenza neutralization. The present invention provides agents for inhibiting influenza infection by bind to the influenza virus and/or hemagglutinin (HA) polypeptides and/or HA receptors, and reagents and methods relating thereto. The present invention provides a system for analyzing interactions between infolds and the interaction partners that bind to them. | 08-18-2011 |
20110224132 | USE OF THE LONG PENTRAXIN PTX3 FOR THE PREVENTION OR TREATMENT OF VIRAL DISEASES - It is described the use of the long pentraxin PTX3 (PTX3) or one of its functional derivatives, for the preparation of a medicament for the prevention or treatment of viral diseases and/or for inhibiting virus activation. | 09-15-2011 |
20110224133 | Highly Potent Peptides To Control Cancer And Neurodegenerative Diseases - This invention provides compositions and method of diminishing or inhibiting autophagy by administering a FLIP protein that binds to Atg3, interfering with the formation of the LC3-Atg4-Atg7-Atg3 conjugation complex necessary for autophagy induction. This invention also provides FLIP peptide fragments that promote or induce autophagy by interfering with the activity of FLIP. | 09-15-2011 |
20110245154 | Methods and Compositions for Treating Viral or Virally-Induced Conditions - Provided are methods and compositions for the prevention and/or treatment of viral conditions, virally-induced conditions and inflammatory conditions. The methods can comprise administering to a subject a viral inducing agent with an antiviral agent, and optionally an additional agent. The viral inducing agent can be a HDAC inhibitor administered orally. | 10-06-2011 |
20110257080 | Hepatitis B Virus Compositions and Methods of Use - A polypeptide comprising a preS1 region of hepatitis B virus (HBV), or a fragment thereof, and/or the preS2 region of HBV or a fragment thereof, and methods of use to inhibit virus infection are disclosed. A lentivirus comprising hepatitis B virus (HBV) envelope proteins, or a fragment thereof, and/or the L envelope protein of HBV and/or the M envelope protein of HBV or a fragment thereof, and/or the S envelope protein of HBV or a fragment thereof, and methods of use of this lentivirus HBV pseudovirus as a gene therapy to target hepatocytes for the administration of therapeutic agents are also disclosed. | 10-20-2011 |
20110257081 | MULTIGAND CONSTRUCTS - Multiligand constructs and intermediate multivalent constructs for use in their preparation are described. The multiligand constructs have utility in diagnostic and therapeutic applications. | 10-20-2011 |
20110263484 | SINGLE CHAIN FC TYPE III INTERFERONS AND METHODS OF USING SAME - The present invention relates to single chain Fc Type III Interferon fusion proteins and methods of using same. The single chain Fc Type III Interferon fusion proteins comprise at least one Type III Interferon, two Fc regions and at least one linker, can be produced in a variety of single chain configurations, and are effector function minus or have a substantially reduced effector function. | 10-27-2011 |
20110269674 | SYNTHETIC OR NATURAL PEPTIDES BINDING PROTEIN PHOSPHATASE 2A, IDENTIFICATION METHOD AND USES - The present invention relates to novel synthetic or natural peptides for use in treating viral or parasitic infections or in the treatment of tumors. The peptides of the present invention are less than 30 amino acids in size, preferably less than 20 amino acids, in particular 15 to 20 amino acids, and in vitro the peptides specifically bind a type 2A protein phosphatase holoenzyme or one of its subunits. The invention also relates to a method for identifying said peptides, and to their uses. | 11-03-2011 |
20110269675 | STRONTIUM-CONTAINING COMPOUNDS FOR USE IN THE PREVENTION OR TREATMENT OF NECROTIC BONE CONDITIONS - A method for the treatment and/or prophylaxis of an osteonecrotic bone disease in a mammal in need thereof, such as, e.g., idiopathic or secondary osteonecrosis, avascular bone necrosis, glucocorticoid induced bone ischemia/osteonecrosis, Legg-Calve-Perthes disease and femoral head necrosis, the method comprising administering an effective dose of a strontium-containing compound (a) to the mammal. A method for the treatment and/or prophylaxis of an osteonecrotic bone disease, such as, e.g., idiopathic or secondary osteonecrosis, avascular hone necrosis, glucocorticoid induced bone ischemia/osteonecrosis and femoral head necrosis, in a mammal who is to be or is treated with a therapeutic agent (b) known to or suspected of inducing apoptosis and/or necrosis of bone cells, the method comprising administering a strontium-containing compound (a) in combination with (b). | 11-03-2011 |
20110281789 | ULBP ANTIBODIES - The invention is directed to purified and isolated novel ULBP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above. ULBP polypeptide can be found on the surface of human B cell lymphomas. Mammalian forms of ULBP polypeptide in isolated or purified forms are provided. In addition, isolated nucleic acids encoding ULBP polypeptides and expression vectors comprising a cDNA encoding ULBP polypeptides are provided. The ULBP polypeptides can be isolated or synthesized and used to prepare antibodies, and in particular monoclonal antibodies, against the polypeptides. The antibodies, in turn, are useful for detecting the presence of ULBP polypeptides in human cell samples, which can be correlated with the existence of a malignant condition in a patient. ULBP polypeptides stimulate IFN-γ production, NK cell proliferation, and CTL activity. | 11-17-2011 |
20120010130 | COMPOSITION FOR PREVENTING VIRUS INFECTION COMPRISING POLY-GAMMA-GLUTAMIC ACID - The present invention relates to a pharmaceutical composition for inhibiting or preventing viral infection, which comprises an effective dose of poly-gamma-glutamic acid (γ-PGA), and more particularly, to a pharmaceutical composition, a functional food, and a feedstuff additive capable of inhibiting viral infection and preventing viral diseases, which comprise poly-gamma-glutamic acid having an infection-inhibiting effect against viruses, such as an influenza virus, inducing respiratory infection or systemic infection, as an effective ingredient. | 01-12-2012 |
20120028887 | LIPOPEPTIDE INHIBITORS OF HIV-1 - The invention provides lipophilic conjugates comprising a short isolated peptide coupled to a hydrophobic moiety, the peptide comprising a sequence derived from the HIV-1 gp41 N-terminal heptad repeat domain, said peptide after conjugation to the hydrophobic moiety possesses anti-fusogenic activity higher than prior to conjugation. The lipophilic conjugates are suitable for treatment of infections caused by human and non-human retroviruses, especially HIV. | 02-02-2012 |
20120040889 | PEPTIDOMIMETIC MACROCYCLES - The present invention provides novel peptidomimetic macrocycles and methods of using such macrocycles for the treatment of viral disease. | 02-16-2012 |
20120040890 | INHIBITOR OF THE URACIL-DNA GLYCOSYLASE ENZYME AND USES THEREOF - The present invention relates to a protein which has the capacity to bind to and inhibit the viral uracil DNA glycosylase (UDG) enzyme and its use as a therapeutic agent; in particular, as an antiviral agent. | 02-16-2012 |
20120058937 | Prodrugs of Neuraminidase Inhibitors - A new class of neuramidase inhibitor prodrugs is provided characterized by a prodrug moiety of a carboxyl group modified to form a carbonyl ethoxy amino acid, a carbonyl ethoxy dipeptide or a carbonyl ethoxy tripeptide, a guanidine group modified to form a carbonyl ethoxy amino acid, a carbonyl ethoxy dipeptide, a carbonyl ethoxy tripeptide; a primary alcohol modified to form an esterified single amino acid, dipeptide or tripeptide of zanavimir of the unaltered therapeutic agent. Exemplary therapeutic agents so modified to form prodrugs include zanavimir, oseltamivir and peramivir. The prodrug has increased oral bioavailability relative to the unaltered neuraminidase inhibitor and is effective in the inhibition of viral infections involving neuraminidase in the viral reproductive cycle. | 03-08-2012 |
20120101031 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS - The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient. | 04-26-2012 |
20120129764 | INFLUENZA A AND B VIRUS REPLICATION-INHIBITING PEPTIDES - A synthesized or isolated influenza virus replication-inhibiting peptide that competitively inhibits protein-protein interaction of the PA and PB1 of both influenza Virus Types A and B and novel in vitro binding screen to identify peptides with antiviral activity against influenza viruses of both type A and B is disclosed. In addition to the well-known pandemic influenza A viruses (such as the 1918 “Spanish” flu or H5N1), both type A and B viruses contribute greatly to the annual recurring epidemics that cause the vast majority of human cases and medical cost. Surprisingly, it was found that the novel virus replication-inhibiting, are able to inhibit protein-protein interaction of the PA and PB1 subunits of the heterotrimeric viral RNA polymerase complex of both influenza virus types A and B. The viral polymerase sub-unit interaction domain turned out as an effective target for the new antivirals, as correct assembly of the three viral polymerase subunits PB1, PB2 and PA is required for viral RNA synthesis and infectivity. | 05-24-2012 |
20120142584 | NOVEL TRANSPORTER CONSTRUCTS AND TRANSPORTER CARGO CONJUGATE MOLECULES - The present invention relates to novel transporter constructs of the generic formula (I) D | 06-07-2012 |
20120178671 | INHIBITION OF NFK-B MEDIATED VIRUS REPLICATION WITH SPECIFIC OLIGOSACCHARIDES - The inventors surprisingly found that specific oligosaccharides are capable of inhibiting viral replication through inhibiting NF-κB activation. The invention thus pertains to a composition comprising pectin (in the form of digalacturonic acid, trigalacturonic acid, polygalacturonic acid), Arabinoxylan from rice bran, β-glucan from bakers yeast, D-Ribose or mixtures there-of for inhibiting viral replication in a mammal with a viral disease. | 07-12-2012 |
20120196792 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS - The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient. | 08-02-2012 |
20120196793 | BIOMARKERS FOR IAP INHIBITOR COMPOUNDS - A method to predict which patients will respond to a IAP inhibiting compound comprising administering an IAP inhibitor compound to a patient/and measuring IL1B, Lymphotoxin alpha (LTa), TWEAK, LIGHT, Fas, TNF alpha or TRAIL levels. | 08-02-2012 |
20120220519 | Peptide Aptamers that Bind to the Rep Proteins of ssDNA Viruses - Polypeptides and fusion proteins that bind to eukaryotic viruses, in particular, eukaryotic single-stranded DNA (ssDNA) viruses are provided. The polypeptides and fusion proteins bind to the replication initiation proteins (Rep) of ssDNA viruses and optionally inhibit viral replication and/or viral infection. The virus can be a plant pathogen or animal pathogen. Consensus sequences used to identify polypeptides that bind to eukaryotic viruses are also provided. | 08-30-2012 |
20120225809 | COMPOUNDS FOR TREATING PAPILLOMA VIRUS INFECTION - The present invention relates to polyamide compositions and therapies for treating cells and subjects infected with papilloma virus. | 09-06-2012 |
20120231997 | RECOMBINANT HUMAN CC10 PROTEIN FOR TREATMENT OF INFLUENZA - Methods of using recombinant human CC10 (rhCC10), also known as recombinant human uteroglobin, to reduce virus titers in the tissues of patients, particularly influenza titers in lung tissues are provided. RhCC10 may be used as a therapeutic in the treatment, cure, or prevention of viral infection, particularly influenza infection. More particularly, methods, including broadly the critical dosage ranges of rhCC10, intravenous and intranasal route of administration, which may be administered to treat, cure or prevent influenza infection are provided. Further provided are compositions useful in the foregoing methods and in administering rhCC10 to humans. | 09-13-2012 |
20120270773 | TRIM5ALPHA MUTANTS AND USES THEREOF - New mutant forms of TRIM5α comprising one or more mutations at amino acid positions corresponding to amino acids 324, 328, 330, 333, 335, 336 and/or 337 of wild-type human TRIM5α and which inhibit retrovirus replication are described. These mutants may be used, for example, in gene therapy applications for the prevention and/or treatment of retroviral infection and associated conditions, such as HIV-1 infection and AIDS. | 10-25-2012 |
20120289458 | TREATMENT OF INFLUENZA VIRUS INFECTION - The present invention provides method for the treatment of an ongoing influenza infection by administering a polypeptide to a subject suffering from an influenza infection. The polypeptide consists of the fusion initiation region (FIR) of an influenza hemagglutinin 2 protein or an 8 to 40 amino acid residue portion thereof. In one embodiment, the polypeptide consists of SEQ ID NO: 4 or an 8 to 40 contiguous amino acid residue portion thereof. The present invention also provides a method of interfering with fusion of an influenza virus envelope with a host cell membrane by contacting the host cell with the FIR polypeptide. | 11-15-2012 |
20120329704 | PROCESS FOR THE PREPARATION OF SUBSTITUTED PROLYL PEPTIDES AND SIMILAR PEPTIDOMIMETICS - The present invention relates to a process for the stereoselective preparation of a compound having the general formula (I) or its respective diastereomers: comprising reacting a compound having the general formula (II) or its diastereomers: with a compound of the general formula III: R | 12-27-2012 |
20130012429 | ANTI-VIRAL THERAPY - This invention relates to a method of treating viral infections, and compounds for use in the treatment of viral infections by modulating the BMP/SMAD signalling pathway. In particular, it relates to methods and compounds for treating hepatitis C virus infection and/or influenza virus infection. It also relates to methods for identifying compounds that are useful in the treatment of viral infections, in particular hepatitis C virus infection and/or influenza virus infection. | 01-10-2013 |
20130029903 | Azuvirin Peptides - Azuvirin peptides are small peptide agents useful in delivering functional moieties, such as sensitizers, chemotherapeutic agents and the like to cancer cells expressing ephrin receptors. The peptides are also useful for administration to a patient suffering from a viral infection, or to an individual facing exposure to a viral infection, especially one caused by the HIV-1 retrovirus. | 01-31-2013 |
20130035284 | SMALL-MOLECULE INHIBITORS OF DENGUE AND WEST NILE VIRUS PROTEASES - The present invention concerns methods and compositions involving small molecule inhibitors for the treatment or prophylaxis of flavivirus infection, such as dengue virus and West Nile virus. | 02-07-2013 |
20130072424 | COMPOUNDS AND METHODS FOR PEPTIDE RIBONUCLEIC ACID CONDENSATE PARTICLES FOR RNA THERAPEUTICS - Compounds comprising condensed particles having diameters less than 1000 nm, wherein the particles comprise one or more double stranded ribonucleic acids (dsRNAs) and one or more peptides. The compounds, compositions and methods are useful for modulating gene expression by RNA interference. | 03-21-2013 |
20130109618 | RNA VIRUS-DERIVED PEPTIDES WITH MODIFIED SIDE CHAINS | 05-02-2013 |
20130130970 | LACTADHERIN-DERIVED PEPTIDES AS ANTIVIRAL AGENTS - The present invention relates to monomeric and multimeric peptidic compounds which have antiviral activity, particularly against integrin-using viruses, more particularly against rotavirus. Further, the present invention refers to compositions comprising said peptidic compounds for medical use or for use as food additives. | 05-23-2013 |
20130143794 | POLYPEPTIDES FOR TREATING AND/OR LIMITING INFLUENZA INFECTION - The present invention provides polypeptides according to the general formulas disclosed herein, which recognize and are strong binders to Influenza A hemagglutinin and can be used, for example, to treat and/or limit development of an influenza infection. The present invention further provides isolated nucleic acids encoding the polypeptides of the invention, recombinant expression vectors comprising the nucleic acids encoding the polypeptides of the invention operatively linked to a suitable control sequence, and recombinant host cells comprising the recombinant expression vectors of the invention. The present invention also provides antibodies that selectively bind to the polypeptides of the invention, and pharmaceutical compositions comprising one or more polypeptides according to the invention and a pharmaceutically acceptable carrier. Additionally, the present invention provides methods for treating and/or limiting an influenza infection, methods for diagnosing an influenza infection, or monitoring progression of an influenza infection, methods for identifying candidate influenza vaccines, and methods for identifying candidate compounds for treating, limiting, and/or diagnosing influenza infection. | 06-06-2013 |
20130150287 | RECOMBINANT PROTEIN FOR INTRACELLULAR DELIVERY OF siRNA AND COMPOSITION COMPRISING THE SAME - The present invention relates to a recombinant protein for siRNA delivery, which allows the efficient intracellular and in vivo delivery of siRNA. More particularly, the present invention relates to a recombinant protein that allows a siRNA binding protein to be located in the interior cavity of a capsid protein of HBV (Hepatitis B virus), in which siRNAs of interest bind to the siRNA binding protein to be encapsulated within the capsid shell, thereby providing stability against the external attack such as nucleases and achieving the efficient intracellular and in vivo delivery of siRNA by its release into the cytosolic space after cell uptake. | 06-13-2013 |
20130150288 | TREATMENT OF VIRAL INFECTIONS - The present invention concerns polypeptides derived from a tandem repeat of apoE | 06-13-2013 |
20130150289 | Crystalline Peptide Epoxy Ketone Protease Inhibitors and the Synthesis of Amino Acid Keto-Epoxides - The invention relates to crystalline peptide keto epoxide compounds, methods of their preparation, and related pharmaceutical compositions. This invention also relates to methods for the preparation of amino acid keto-epoxides. Specifically, allylic ketones are stereoselectively converted to the desired keto epoxides. | 06-13-2013 |
20130150290 | Crystalline Peptide Epoxy Ketone Protease Inhibitors and the Synthesis of Amino Acid Keto-Epoxides - The invention relates to crystalline peptide keto epoxide compounds, methods of their preparation, and related pharmaceutical compositions. This invention also relates to methods for the preparation of amino acid keto-epoxides. Specifically, allylic ketones are stereoselectively converted to the desired keto epoxides. | 06-13-2013 |
20130172238 | METHOD FOR SELECTIVE OLIGONUCLEOTIDE MODIFICATION - Method for producing a modified oligonucleotide, wherein at least one polymer, preferably polyalkylene oxide, and/or a compound is covalently bound to the 5′-end or the 3′-end of the oligonucleotide via native ligation forming a native ligation site, with the proviso that the polymer and/or the compound is not a protein or peptide, if only the 5′-end of the oligonucleotide is modified by binding of the polymer or compound via native ligation. The invention is further directed to a modified oligonucleotide obtainable by the inventive method as well as the use of such modified oligonucleotide for the preparation of a medicament for preventing and/or treating a tumor, formation of metastasis, an immune disease or disorder, a cardiovascular disease or disorder, and/or a viral disease or disorder. | 07-04-2013 |
20130190228 | NOVEL ANTIVIRAL PEPTIDES AGAINST INFLUENZA VIRUS - The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections. | 07-25-2013 |
20130196902 | Beta-Arrestin Effectors and Compositions and Methods of Use Thereof - This application describes compounds acting as, for example, β-arrestin effectors and uses thereof, in, for example, the treatment of chronic and acute cardiovascular diseases. | 08-01-2013 |
20130203655 | METHODS FOR PREVENTING OR TREATING VIRAL INFECTION - The present invention provides methods to prevent or treat flavivirus infection, and assays for identifying agents which treat flavivirus infection. The present invention also provides compositions for preventing flavivirus infection and a kit for screening an agent that prevents or treats viral infection. | 08-08-2013 |
20130237474 | Biosynthetic Polypeptide Fusion Inhibitors - Modified biosynthetic polypeptide fusion inhibitors, methods for manufacturing, and uses thereof are provided. | 09-12-2013 |
20130261048 | Composition Comprising a Peptide and an Inhibitor of Viral Neuraminidase - Described is a composition comprising—a peptide which consists of 7-17 adjacent amino acids and comprises the hexamer TX | 10-03-2013 |
20130261049 | ALPHABODIES SPECIFICALLY BINDING TO CLASS-I VIRAL FUSION PROTEINS AND METHODS FOR PRODUCING THE SAME - Single-chain Alphabodies that comprise an alpha-helical binding region which mediates binding to a first fusion-driving region of a class-1 viral fusion protein and which structurally mimics a second fusion-driving region of said class-1 viral fusion protein, wherein said first and second fusion-driving regions of said class-1 viral fusion protein are regions which interact to drive the fusion between a virus displaying said class-1 viral fusion protein and a target cell. | 10-03-2013 |
20130267460 | Methods of Inhibiting Alphavirus Replication and Treating Alphavirus Infection - The invention provides methods of inhibiting alphavirus replication and treating alphavirus infection. | 10-10-2013 |
20130274176 | BETA-ARRESTIN EFFECTORS AND COMPOSITIONS AND METHODS OF USE THEREOF - This application describes a family of compounds acting as β-arrestin effectors. Such compounds may provide significant therapeutic benefit in the treatment of chronic and acute cardiovascular diseases. | 10-17-2013 |
20130281361 | METHODS OF TREATING AND PREVENTING RHINOVIRUS INFECTION - The present invention relates to methods of treating or preventing non-enveloped viral infection and/or disease caused by non-enveloped virus infection, particularly a viral infection caused by rhino virus. The methods comprise administering to an individual in need thereof an effective amount of a defensin peptide. The defensin peptide may be selected from α-, β-, or θ-defensins. | 10-24-2013 |
20130331313 | METHODS AND COMPOSITIONS FOR TREATING VIRAL OR VIRALLY-INDUCED CONDITIONS - Provided are methods and compositions for the prevention and/or treatment of viral conditions, virally-induced conditions and inflammatory conditions. The methods can comprise administering to a subject a viral inducing agent with an antiviral agent, and optionally an additional agent. The viral inducing agent can be a HDAC inhibitor administered orally. | 12-12-2013 |
20140011734 | CYCLIC PEPTIDES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF THE PLATELET ADHESION - The present invention relates to compounds of the Formula (I), in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, X1, X2, X3 and X4 have the meanings indicated in the claims, and which are valuable pharmacologically active compounds. They are reversible inhibitors of the interaction between the plasma protein von Willebrand factor (vWF) and the blood platelet receptor glycoprotein Ib-IX-V complex (GPIb), and are suitable, for example, for the therapy and prophylaxis of athero-thrombotic diseases. The invention furthermore relates to processes for the preparation of compounds of the Formula (I), their use, in particular as active ingredients in medicaments, and pharmaceutical compositions comprising them. | 01-09-2014 |
20140045742 | SERPIN-FINGER FUSION POLYPEPTIDE - The current invention comprises a fusion polypeptide comprising a serpin-finger polypeptide conjugated to a biologically active polypeptide optionally via a peptidic linker polypeptide. Another aspect is a protein complex of the serpin-finger fusion polypeptide and a serpin, wherein the fusion polypeptide is incorporated in the serpin into the middle of beta-sheet A as strand 4a. Also an aspect of the current invention is the in vitro preparation of the protein complex. The serpin-finger polypeptide targets and anchors the biologically active polypeptide with high affinity and functional spatial orientation. | 02-13-2014 |
20140045743 | COMPOSITIONS AND METHODS FOR CORONAVIRUS INHIBITION - The present invention provides compositions and methods for treating a coronavirus infection. A method embodiment comprises administering a polypeptide (preferably in a biocompatible pharmaceutical carrier) to a subject suffering from a coronavirus infection. The polypeptide comprises or consists of at least a portion of the fusion initiation region (FIR) of a coronavirus fusion protein. In some embodiments, the polypeptide comprises or consists of a sequence selected from SEQ ID NO: 2, 22, 23, 24, and 25 or an 8 to 40 contiguous amino acid residue portion thereof. | 02-13-2014 |
20140107014 | Methods and systems for adenovirus interaction with desmoglein 2 (DSG2) - The present invention provides compositions, compounds, and methods relating to recombinant adenoviral-based polypeptides for treating disorders associated with epithelial tissues. | 04-17-2014 |
20140113855 | Modified Release Formulations for Oprozomib - This disclosure features modified release pharmaceutical formulations (e.g., extended release pharmaceutical formulations; e.g., solid dosage forms, e.g., tablets) that are useful for the oral administration of oprozomib, or a pharmaceutically acceptable salt thereof, to a human or animal subject as well as methods of making and using the formulations. | 04-24-2014 |
20140194347 | INFLUENZA INHIBITING COMPOSITIONS AND METHODS - The present invention provides peptides, peptide analogs, peptide derivatives and pharmaceutical compositions useful for treating or preventing influenza infections or preventing the person-to-person transmission of an influenza infection. A peptide of the invention comprises an influenza virus-cell fusion inhibiting portion of the fusion initiation region (FIR) of a wild-type influenza hemagglutinin 2 protein or a variant thereof. In a preferred embodiment, a peptide of the invention consists of 8 to 40 consecutive amino acid residues a portion of a wild-type influenza hemagglutinin 2 protein or a variant thereof, the portion of the protein comprising the FIR of the protein and up to five amino acid residues on the amino-terminal and carboxy-terminal sides of the FIR. | 07-10-2014 |
20140194348 | METHOD OF INHIBITING PAPILLOMAVIRUS PROLIFERATION AND TREATING PAPILLOMAVIRUS INFECTION - Methods for inhibiting virus proliferation and treating an individual having a papillomavirus infection preventing viral infection are disclosed. The methods include the steps of providing a composition comprising a plurality of papillomavirus virus-like particles or capsomeres and contacting papillomavirus-infected tissue of an individual with the composition under conditions effective to inhibit papillomavirus proliferation or treat the papillomavirus infection in the individual. | 07-10-2014 |
20140206603 | ENGINEERED POLYPEPTIDE AGENTS FOR TARGETED BROAD SPECTRUM INFLUENZA NEUTRALIZATION - The present invention provides novel agents for broad spectrum influenza neutralization. The present invention provides agents for inhibiting influenza infection by bind to the influenza virus and/or hemagglutinin (HA) polypeptides and/or HA receptors, and reagents and methods relating thereto. The present invention provides a system for analyzing interactions between infolds and the interaction partners that bind to them. | 07-24-2014 |
20140243256 | ARENAVIRUS INHIBITING PEPTIDES AND USES THEREFOR - The present invention describes peptides which inhibit fusion of an arenavirus (e.g., Pichinde virus; PICV) with a host cell membrane. The arenavirus inhibiting (AVI) peptides described herein comprise a segment of the GP2 protein of an arenavirus. The AVI peptides are useful for inhibiting arenavirus-to-host cell membrane fusion and for treating arenavirus infections. In a particular embodiment, the arenavirus inhibiting peptide comprises a segment of PICV glycoprotein 2 (PICV GP2; SEQ ID NO: 1), Tamiami virus (TAMV) GP2 (SEQ ID NO: 14), or Lassa virus (LASV) GP2 (SEQ ID NO: 15). In particular, the segment is selected from a region of an arenavirus GP2 extending from the N-terminus into the first half of the FIR (i.e., from residues 1 through 105 of SEQ ID NO: 1, SEQ ID NO: 14, or SEQ ID NO: 15). | 08-28-2014 |
20140256618 | Haprolid and Derivatives Thereof as Inhibitors of HCV - The present invention describes new compounds (e.g. Haprolid) of formula (I) and their use as antiviral agents such as inhibitors of hepatitis C virus (HCV): | 09-11-2014 |
20140256619 | USE OF AVERMECTIN DERIVATIVE FOR INCREASING BIOAVAILABILITY AND EFFICACY OF MACROCYLIC LACTONES - The present invention relates to the use of avermectin derivative as a drug for the treatment of parasitic infections. The avermectin derivative is represented by the formula (I) wherein: (i) R | 09-11-2014 |
20140274883 | NOVEL ANTIVIRAL COMPOUNDS FROM MARINE EXTRACTS - The subject invention pertains to novel biologically active extracts from marine algae and to biologically active fractions and components of these extracts. These extracts have been shown to possess antiviral properties. Pharmaceutical compositions comprising these extracts, or comprising biologically active fractions or components of these extracts, could be used in the treatment of viral diseases including influenza. | 09-18-2014 |
20140303073 | ANTISENSE ANTIVIRAL COMPOUND AND METHOD FOR TREATING INFLUENZA VIRAL INFECTION - The present invention relates to antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Orthomyxoviridae family and in the treatment of a viral infection. The compounds are particularly useful in the treatment of influenza virus infection in a mammal. Exemplary antisense antiviral compounds are substantially uncharged, or partially positively charged, morpholino oligonucleotides having 1) a nuclease resistant backbone, 2) 12-40 nucleotide bases, and 3) a targeting sequence of at least 12 bases in length that hybridizes to a target region selected from the following: a) the 5′ or 3′ terminal 25 bases of the negative sense viral RNA segment of Influenzavirus A, Influenzavirus B and Influenzavirus C; b) the terminal 30 bases of the 5′ or 3′ terminus of the positive sense vcRNA; c) the 45 bases surrounding the AUG start codon of an influenza viral mRNA and; d) 50 bases surrounding the splice donor or acceptor sites of influenza mRNAs subject to alternative splicing. | 10-09-2014 |
20140323392 | METHODS AND COMPOSITIONS RELATED TO INHIBITION OF VIRAL ENTRY - Disclosed herein are compositions and methods for inhibiting viral entry. | 10-30-2014 |
20140323393 | Uses Of Peptides to Treat Brain Injury and Disease - A method of treating loss of brain function in a patient comprising the steps of preparing a composition comprising a D peptide and a pharmaceutically acceptable carrier. The D peptide has the general structure: A-B-C-D-E-F-G-H in which
| 10-30-2014 |
20150038408 | Polypeptides for treating and/or limiting influenza infection - The present invention provides polypeptides that recognize and are strong binders to Influenza A hemagglutinin and can be used, for example, to treat and/or limit development of an influenza infection. The present invention further provides isolated nucleic acids encoding the polypeptides of the invention, recombinant expression vectors comprising the nucleic acids encoding the polypeptides of the invention operatively linked to a suitable control sequence, and recombinant host cells comprising the recombinant expression vectors of the invention. The present invention also provides antibodies that selectively bind to the polypeptides of the invention, and pharmaceutical compositions comprising one or more polypeptides according to the invention and a pharmaceutically acceptable carrier. Additionally, the present invention provides methods for treating and/or limiting an influenza infection, methods for diagnosing an influenza infection, or monitoring progression of an influenza infection, methods for identifying candidate influenza vaccines, and methods for identifying candidate compounds for treating, limiting, and/or diagnosing influenza infection. | 02-05-2015 |
20150051139 | Mucins as Antiviral Compounds - The invention provides methods, and compositions for performing the methods, that reduce the diffusion or overall mobility of a virus on a surface, such as a biological surface using a purified mucin. The methods can reduce the infectivity of a virus for a cell on the surface. In particular embodiments, the mucin can be a non-human mucin, such as a procine gastric mucin. | 02-19-2015 |
20150065418 | NEUREGULIN BASED METHODS AND COMPOSITIONS FOR TREATING CARDIOVASCULAR DISEASES - The present invention relates to compositions and methods for preventing, treating or delaying various cardiovascular diseases or disorders in mammals, particularly in humans. More particularly, the present invention provides for compositions and methods for preventing, treating or delaying various cardiovascular diseases or disorders using, inter alia, a neuregulin protein, or a functional fragment thereof, or a nucleic acid encoding a neuregulin protein, or a functional fragment thereof, or an agent that enhances production and/or function of said neuregulin. | 03-05-2015 |
20150080293 | LECTINS AND USES THEREOF - The present invention relates to chemical compounds, methods for their discovery, and their therapeutic and research use. In particular, the present invention provides antiviral and antimicrobial lectin compounds and methods of their use. | 03-19-2015 |
20150105315 | Polypeptide Fragments Comprising Endonuclease Activity and Their Use - The present invention relates to polypeptide fragments comprising an amino-terminal fragment of the PA subunit of a viral RNA-dependent RNA polymerase or variants thereof possessing endonuclease activity, wherein said PA subunit is from a virus belonging to the Orthomyxoviridae family. This invention also relates to (i) crystals of the polypeptide fragments which are suitable for structure determination of said polypeptide fragments using X-ray crystallography and (ii) computational methods using the structural coordinates of said polypeptide to screen for and design compounds that modulate, preferably inhibit the endonucleolytically active site within the polypeptide fragment. In addition, this invention relates to methods identifying compounds that bind to the PA polypeptide fragments possessing endonuclease activity and preferably inhibit said endonucleolytic activity, preferably in a high throughput setting. This invention also relates to compounds and pharmaceutical compositions comprising the identified compounds for the treatment of disease conditions due to viral infections caused by viruses of the Orthomyxoviridae family. | 04-16-2015 |
20150105316 | Beta-Arrestin Effectors And Compositions And Methods Of Use Thereof - This application describes compounds acting as, for example, β-arrestin effectors and uses thereof, in, for example, the treatment of chronic and acute cardiovascular diseases. | 04-16-2015 |
20150133367 | Novel Alpha-Helical Peptidomimetic Inhibitors And Methods Using Same - The present invention includes a novel class of highly specific protease inhibitors. In one embodiment, the inhibitors of the invention are α-helical in structure. In another embodiment, the present invention represents the first demonstration of a highly specific cysteine protease inhibitor. | 05-14-2015 |
20150329596 | ANTIVIRAL COMPOUNDS AND METHODS FOR TREATING INFECTIONS CAUSED BY DOUBLE-STRANDED DNA VIRUSES - The present invention relates to polyamide compounds and their use in pharmaceutical compositions and in medical applications for the treatment of human papillomavirus infections and/or polyomavirus infections. | 11-19-2015 |
20150337015 | ANTIVIRAL RIFT VALLEY FEVER VIRUS PEPTIDES AND METHODS OF USE - The invention entails synthetic short peptides based on Rift Valley Fever Virus (RVFV) fusion protein. The peptides are broad-spectrum antivirals, and are useful for prophylactic treatment against or therapeutic treatment of infection by hemorrhagic fever viruses, such as RVFV, Ebola Virus, and Andes Virus, as well as vesicular stomatitis virus. | 11-26-2015 |
20150344521 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES - Provided are compounds of Formula I: | 12-03-2015 |
20160024155 | Polypeptides for treating and/or limiting influenza infection - Polypeptides are disclosed herein, which recognize and are strong binders to Influenza A hemagglutinin and can be used, for example, to treat and/or limit development of an influenza infection. | 01-28-2016 |
20160041181 | NMR ASSAY TO SCREEN PROTEIN-PROTEIN INTERACTION INHIBITORS - This invention relates generally to a field of rational drug design. In particular, the present invention relates to a | 02-11-2016 |
20160068573 | PEPTIDOMIMETIC MACROCYCLES - The present invention provides novel peptidomimetic macrocycles and methods of using such macrocycles for the treatment of viral disease. | 03-10-2016 |
20160082074 | COMPOSITIONS AND METHODS FOR TREATING CORONAVIRUS INFECTION - The invention relates to the use of non-immunosuppressive cyclophilin inhibitors in the treatment of Coronavirus infection in a patient. | 03-24-2016 |
20160089418 | THERAPEUTIC COMPOSITIONS FOR NEUTRALIZING TYPE I INTERFERONS, AND METHODS OF USE - The inventions describe here cover therapeutic compositions, and methods of use, for neutralizing Type I interferons in a mammal. The compositions contain a soluble Orthopoxvirus IFN-binding protein that is modified to remove the cell-binding region, and that specifically binds to Type I IFNs, and a pharmaceutically acceptable carrier or excipient. Another variation of the invention entails a novel IFN-binding protein that is modified to remove the cell-binding region and the signal sequence. | 03-31-2016 |
20160095897 | PAR-4 ANTAGONISTS FOR USE IN THE TREATMENT OR PREVENTION OF INFLUENZA VIRUS TYPE A INFECTIONS - The present invention provides methods and compositions (such as pharmaceutical compositions) comprising PAR4 antagonists for treating or preventing influenza virus type A infections, in particular H1N1 infection. PAR4 antagonists may be combined with a PAR2 agonist or a PAR1 antagonist. | 04-07-2016 |
20160113929 | METHODS AND COMPOSITIONS FOR TREATING VIRAL OR VIRALLY-INDUCED CONDITIONS - Provided are methods and compositions for the prevention and/or treatment of viral conditions, virally-induced conditions and inflammatory conditions. The methods can comprise administering to a subject a viral inducing agent with an antiviral agent, and optionally an additional agent. The viral inducing agent can be a HDAC inhibitor administered orally. | 04-28-2016 |
20160130304 | NOVEL CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C INFECTION - The present invention relates to novel cyclosporine analogues having antiviral activity against HCV and useful in the treatment of HCV infections. More particularly, the invention relates to novel cyclosporine analogue compounds, compositions containing such compounds and methods for using the same, as well as processes for making such compounds. | 05-12-2016 |
20160152984 | ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS | 06-02-2016 |
20160199441 | PAN-ANTIVIRAL PEPTIDES FOR PROTEIN KINASE INHIBITION | 07-14-2016 |
20160250278 | PEPTIDOMIMETIC MACROCYCLES | 09-01-2016 |
20160375092 | PEPTIDE AND A USE THEREOF - The disclosure relates to a peptide (SEQ ID NO: 5), the use of said peptide for the treatment of the symptoms associated with pain, the use of said peptide for the inhibition of the activity of influenza virus and a pharmaceutical composition containing the peptide. | 12-29-2016 |
20160376321 | A NOVEL SARS IMMUNOGENIC COMPOSITION - Embodiments of the disclosure concern immunogenic compositions and methods for treating or preventing Severe acute respiratory syndrome (SARS). The compositions and methods concern a portion of the receptor-binding domain (RBD) of the SARS-CoV spike protein. In at least particular cases, a mutated version of a portion of the RBD is utilized, such as a deglycosylated mutant of the RBD. | 12-29-2016 |
20190142792 | ANTIVIRAL EPICATECHINS, EPICATECHIN OLIGOMERS, OR THIOLATED EPICATECHINS FROM THEOBROMA CACAO FOR TREATMENT OF GENITAL WARTS | 05-16-2019 |